Global Therapeutic Vaccines Market is valued at USD 26.66 Billion in 2020 and is expected to reach USD 88.52 Billion by 2027 with a CAGR of 18.7% over the forecast period.
Global Therapeutic Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis to 2022-2027, Increasing number of chronic diseases, rising prevalence of infectious diseases followed by surging government initiatives for disease control are major factors anticipated to drive the Global Therapeutic Vaccines Market
The vaccines used for the treatment of diseases by stimulating immune responses are known as therapeutic vaccines. Therapeutic vaccines are used to treat cancer by producing immunity against certain cancer cells also used in the prevention of tuberculosis and HIV, hepatitis, and cholera. Therapeutic vaccines are of two types’ autologous vaccines and allogeneic vaccines. Autologous vaccines cells or immune cells from a person's own body are harvested to make a vaccine for that person.
Allogeneic vaccines are engineered in the lab and they are mostly used to develop therapeutic vaccines for cancer. Different types of therapeutic vaccines with diverse mechanisms of action are produced from these cells such as antigenic vaccines, dendritic vaccines, and DNA vaccines. The first therapeutic vaccine was approved in 1990 for the treatment of carcinoma in situ of the bladder. Therapeutic vaccines are stimulating the field of vaccine research. The therapeutic vaccine field is growing with FDA-approved vaccines. Viral diseases like HIV, hepatitis B, or HPV can be cured by therapeutic vaccines.
The COVID-19 has shown a positive impact on the global therapeutic vaccines market. The COVID-19 pandemic has escorted in a new era for vaccines and immunization. The ongoing research for vaccine development against COVID-19 positively impacted the global therapeutic vaccines market. The demand for vaccines increased during pandemics due to the outbreak and seriousness of COVID-19.
The global therapeutic vaccines market is segmented into on the basis of type, technology and region & country level. On the basis of type, the global therapeutic vaccines market is segmented into addiction vaccines, autoimmune disease vaccines, infectious disease vaccines and neurological disease vaccines. On the basis of technology, the market is classified into autologous vaccines allogeneic vaccines and others.
The regions covered in the global therapeutic vaccines market report are North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. On the basis of country level, the market of global therapeutic vaccines is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East Asia, GCC, Africa, etc.
Some of the key players for global therapeutic vaccines market are:
December 21st, 2021; Massachusetts-based Biopharmaceutical Company had announced that the U.S. Food and Drug Administration’s (FDA) had approved the Company’s Investigational New Drug (IND) application to proceed with initiation of Phase 2 clinical test of Brilacidin in hospitalized patients with COVID-19. Brilacidin might be a Host Defense Protein (HDP) mimetic addressing a supplanting class of drugs with antiviral, calming, and anti-bacterial properties, said Innovation Pharmaceuticals. Brilacidin is one among the few drugs targeting COVID-19 tested in human trials for additional clinical indications, providing recognized protection and user data on over 460 subjects, to help against pandemics.
One of the major factors driving the growth of the global therapeutic vaccines market is the increasing number of chronic diseases. Therapeutic vaccines address a reasonable choice for dynamic immunotherapy of cancers that mean treating late-stage infection by utilizing a patient's own immune system. There are various therapeutic vaccines being developed and many are coordinated against cancers like glioblastoma, skin cancer, breast cancer, cervical cancer, lungs cancer, and pancreatic cancers. Thus, the demand for the therapeutic vaccine market has increased due to the increasing prevalence of chronic diseases. For instance, Cancer is a main cause of death around the world, representing almost 10 million deaths in 2020. In addition, another major factor for the growth of the global therapeutic vaccines market is the growing prevalence of infectious diseases.
The COVID -19 is the most recent infectious viral disease and to battle with it, the development of an effective and safe vaccine was urgently needed. Researchers are developing vaccines against SARS-CoV-2; four different types of vaccines are virus-based vaccine, protein-based vaccine, viral vector-based vaccine, and nucleic acid-based vaccine are developed during a pandemic. For instance, as per the news published on 23rd August 2021, FDA approved the Pfizer-BioNTech COVID-19 vaccine. Thus, the development of therapeutic vaccines for COVID-19 tremendously increased the global therapeutic vaccines market.
Furthermore, rising government initiatives for disease control also drive the global therapeutic vaccines market. The life-threatening diseases pushed government institutions and organizations around the world to launch hundreds of research studies on diagnosis, prevention, and treatment strategies and vaccine development which fuelled the market growth. For example, as per the news published on 17th April 2020, the National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership for developing the most promising treatments and vaccines. Thus, these factors augment the growth of the global therapeutics market in the forecast period.
However, the high cost of therapeutic vaccines hampering the growth of the global therapeutic vaccine market. In spite of that, the development of Human Papilloma virus-mediated malignancies and research and development in therapeutic vaccines can provide various opportunities for the further growth of the global therapeutic vaccine market over the forecast period.
North America dominates the global therapeutic vaccine market due to the increasing number of cancer patients, the development of new technological advanced vaccines support the development of new vaccines, and research and development and clinical trials in vaccines. An increasing number of cancer patients drives the market in this region. For instance, according to the American Cancer Society, in 2021, 1,898,160 new cancer cases and 608,570 disease deaths are projected to happen in the United States. In addition to that, research and development also drive the therapeutic vaccine market in this region. For example, as per the news published on 17th February 2021, BioVaxys Technology Corp. was developing a new ovarian cancer 'therapeutic' vaccine.
The Asia Pacific is the fastest-growing market in the global therapeutic vaccine market due to the rising prevalence of various infectious diseases and aging population and improving healthcare infrastructure. For instance, as of 17th December 2021 according to WHO (World Health Organization), there have been 34,726,049 confirmed cases of covid-19. In addition to that, vaccine developments and trials also add growth to the market. For example, BharatBiotech Submits Phase 3 Clinical Trial Data of Intranasal Vaccine as Booster Shot. Additionally, for the development of the COVID vaccine, the Serum Institute of India has tied up with an American biotechnology firm that is in a pre-clinical trial phase, but the company expects it to be ready by early 2022. These collaborations and the launch of vaccines are boosting the growth of the global therapeutic vaccines in Asia Pacific region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 26.66 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 88.52 Billion|
|Tables, Charts & Figures:||175|
|therapeutic vaccines Manufacturers||Agenus, Inc., GlaxoSmithKline, Novartis AG, Pfizer, Argos Therapeutics Inc., Merck & Co., Celldex Therapeutic Inc., Cytos Biotechnology AG, Dendreon Corp, others|
|Segments Covered||By Type, By Technology|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®